{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"PACUPod: Critical Care","title":"Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial summary","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/563559c8\"></iframe>","width":"100%","height":180,"duration":299,"description":"{\n  \"podcast\": \"PACUPod\",\n  \"episode_title\": \"IsoCOMFORT: Inhaled isoflurane for sedation of mechanically ventilated children in intensive care\",\n  \"episode_description\": \"A concise AI-assisted overview of the IsoCOMFORT trial (Lancet Respiratory Medicine) comparing inhaled isoflurane sedation versus intravenous midazolam in mechanically ventilated children. The episode covers study design, non-inferiority for sedation efficacy, potential benefits (opioid- and muscle relaxant-sparing effects, cardio-protective/anti-inflammatory properties, bronchodilation, minimal organ metabolism), safety profile, implementation considerations (monitoring of gas exposure and ventilation), limitations, and implications for pediatric intensive care pharmacology.\",\n  \"study_details\": {\n    \"design\": \"Multicentre, randomized, active-control, assessor-masked, non-inferiority phase 3 trial\",\n    \"population\": \"Mechanically ventilated children in the pediatric intensive care unit\",\n    \"interventions_comparison\": \"Inhaled isoflurane sedation vs intravenous midazolam\",\n    \"primary_outcome\": \"Sedation efficacy (non-inferiority)\"\n  },\n  \"key_findings\": [\n    \"Inhaled isoflurane achieved non-inferior sedation efficacy compared with intravenous midazolam\",\n    \"Reduced opioid and muscle relaxant use with inhaled isoflurane\",\n    \"Potential cardio-protective, anti-inflammatory, and bronchodilator effects\",\n    \"Minimal hepatic and renal metabolism of isoflurane\",\n    \"Safety profile comparable between groups\"\n  ],\n  \"clinical_implications\": [\n    \"Consider inhaled isoflurane as a viable alternative sedative in PICUs\",\n    \"Potential for faster recovery and opioid-sparing benefits\",\n    \"Necessity for protocols monitoring anesthetic gas exposure and ventilation\",\n    \"Importance of team education on inhaled-sedation workflows\"\n  ],\n  \"limitations\": [\n    \"Full safety data not publicly available at abstract publication time\",\n    \"Non-inferiority design may miss very small differences\",\n   ...","thumbnail_url":"https://img.transistorcdn.com/W5ppyJiVvpeq5HNrnsz_zaMmU5rmab3dOuTiTdwfeYQ/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hMTdi/ZTcyYTUyYTdmMmY2/Y2VmYzc4ZmIwYzA4/NTdlMC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}